Good day,

Connectus Global would like to thank you for your commitment to the safety and welfare of the entire community as well as the determination to do your part to ensure a safe "Return to Normal".

***Please read further to learn who we are, why we are doing this and what it means to you.

Connectus Services Ltd. o/a Connectus Global is a provider of real-time location systems (RTLS) that track employee and asset whereabouts in real time. The Company's systems improve business process immensely, creating safer and more efficient operations. Connectus, based in Alberta, Canada, also creates digital documents & Electronic Permit to Work (PTW) solutions on the job site which increase safety and efficiency. The Company's products are integrated into consumer products giant, Honeywell's exceedingly popular Esperion System.

The COVID virus slowed down our projects, the same as many others, but what made us begin to move in a new direction was the conversation with one of our close friends as he was returning to work at a Nuclear facility in Ontario. Amid the pandemic, all that was asked of him before returning was to sign a self declaration form. He was concerned that there were no questions as to travel habits, social distancing, testing of any kind. This put him at an increased risk as well as the workers around him and then even further than that, their families when they go home at the end of the day.

This process, or lack thereof, seemed to lose. That prompted Connectus to begin the development of our QC-Clock app. The QC-Clock is a new mobile app that securely integrates antibody testing results and self-quarantining behaviours to create a structured compliance record, that over time, will permit safer workforce, large event, and travel reengagement.

We then combined this app with the COVID test kit to allow anyone, regardless of age, race, location, financial status….to have access to "peace of mind". This package is a tool to support the government at all levels with the strategy they have outlined to keep everyone safe and allow the community to return to normal at a faster, safer rate.

This test is provided to us from the OEM Maccura and has received the EUA (Emergency Use Authorization) from the FDA (Food and Drug Administration). You can find the direct product information on the company's website.

https://www.maccura.com/en/product/uwMA7UmFXAE-.html

Limitations related to the intended use of serological tests

Based on the information available at the present time, Health Canada will not authorize serological tests intended to be used for diagnosis or for self-testing. As research evolves and we learn more about the virus, the disease and the immune response, the requirements in this Guidance may be updated accordingly based on available scientific evidence.

The following statements should be included as limitations of serological tests:

- This assay is not intended to be used for screening patients or as an aid for diagnosis of patients with suspected COVID-19 infection.
- This assay is not intended for home testing (or self-testing).
- Negative results do not preclude SARS-CoV-2 infection and should not be used as the sole basis for patient management decisions.
- Negative results must be combined with clinical observations, patient history, and epidemiological information.
- False negative results can occur in elderly and immunocompromised patients.
- Use in conjunction with the testing strategy outlined by public health authorities in your area.
- IgM antibodies may not be detected in the first few days of infection; the sensitivity of the test early after infection is unknown.
- Results are for the detection of SARS-CoV-2 antibodies. IgM antibodies to SARS-CoV-2 are generally detectable in blood several days after initial infection, although levels over the course of infection are not well characterized. IgG antibodies to SARS-CoV-2 become detectable later following infection. **At this time, it is unknown how long IgM or IgG antibodies may persist following infection.**
- Positive results for both IgG and IgM could occur after infection and can be indicative of acute or recent infection [and successful immune response to a vaccine, once developed].
- False positive results for IgM and IgG antibodies may occur due to cross-reactivity from pre-existing antibodies or other possible causes.
- The presence of specific antibodies is a sign of previous or current infection and can also be used to determine the efficacy of treatment.
- Laboratories are required to report all positive results to the appropriate public health authorities

This brand of COVID 19 Test Kit is certified for use in the following manner:

- USA – Human Use
- Europe – Human Use
- Asia Pacific – Human Use
- Canada – Pet Use (Human Use is under review from Health Canada)

If you have any questions or concerns around this product or the use of it, please send us an email at info@connectusglobal.com.

Take Care and Stay Safe,

Connectus Global Team

www.connectusglobal.com
www.PPEtome.ca